

CITATION REPORT

List of articles citing

Cardiovascular effects of tadalafil

DOI: 10.1016/s0002-9149(03)00074-2

American Journal of Cardiology, 2003, 92, 37M-46M.

Source: <https://exaly.com/paper-pdf/35020278/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|----|-----------|
| 103 | Overview of phosphodiesterase 5 inhibition in erectile dysfunction. <i>American Journal of Cardiology</i> , 2003 , 92, 9M-18M | 3 | 160 |
| 102 | Sexual activity in patients with angina. 2003 , 290, 3129-32 | | 29 |
| 101 | A 66-year-old man with sexual dysfunction. 2004 , 291, 2994-3003 | | 19 |
| 100 | Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. 2004 , 17, 239-250 | | 1 |
| 99 | The efficacy and safety of tadalafil: an update. 2004 , 93, 1276-81 | | 158 |
| 98 | Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. 2004 , 1, 161-7 | | 38 |
| 97 | Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. 2004 , 45, 339-44; discussion 344-5 | | 105 |
| 96 | Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. 2004 , 27, 120-5 | | 22 |
| 95 | Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. 2004 , 5, 467-71 | | 37 |
| 94 | Reply. 2004 , 43, 2150-2151 | | 2 |
| 93 | Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. 2004 , 44, 1488-96 | | 86 |
| 92 | New phosphodiesterase inhibitors in the treatment of erectile dysfunction. 2004 , 5, 2241-9 | | 11 |
| 91 | New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88 | | 69 |
| 90 | Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. 2004 , 110, 3149-55 | | 143 |
| 89 | Erectile dysfunction: evaluation and new treatment options. 2004 , 66, 664-71 | | 29 |
| 88 | Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. 2004 , 1, 185-196 | | |
| 87 | The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. 2005 , 60, 459-68 | | 19 |

| | | | |
|----|---|---|-----|
| 86 | Erectile dysfunction in patients with coronary artery disease. 2005 , 17, 209-15 | | 19 |
| 85 | A case of erectile dysfunction and risk factors for coronary artery disease. 2005 , 17 Suppl 1, S7-S11 | | 3 |
| 84 | Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <i>American Journal of Cardiology</i> , 2005 , 96, 313-21 | 3 | 216 |
| 83 | Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. <i>American Journal of Cardiology</i> , 2005 , 96, 32M-36M | 3 | 17 |
| 82 | Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. <i>American Journal of Cardiology</i> , 2005 , 96, 37M-41M | 3 | 36 |
| 81 | Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. <i>American Journal of Cardiology</i> , 2005 , 96, 42M-46M | 3 | 63 |
| 80 | Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <i>American Journal of Cardiology</i> , 2005 , 96, 85M-93M | 3 | 99 |
| 79 | Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. 2005 , 2, 415-25; discussion 425-7 | | 80 |
| 78 | Nitric oxide and penile erectile function. 2005 , 106, 233-66 | | 163 |
| 77 | Hipertensi3n arterial, medicaci3n antihipertensiva y disfunci3n er3ctil: una perspectiva basada en la evidencia. 2005 , 3, 13-30 | | 5 |
| 76 | The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. 2005 , 45, 987-1003 | | 127 |
| 75 | Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. 2005 , 6, 75-84 | | 43 |
| 74 | Phosphodiesterase 5 inhibitors for erectile dysfunction. 2005 , 39, 1286-95 | | 61 |
| 73 | A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. 2005 , 65, 1621-50 | | 133 |
| 72 | Chapter 1: The management of erectile dysfunction: an AUA update. 2005 , 174, 230-9 | | 255 |
| 71 | Safety and tolerability of oral erectile dysfunction treatments in the elderly. 2005 , 22, 323-38 | | 5 |
| 70 | Erectile Dysfunction in the Patients with Cardiovascular Disease. 2006 , 47, 279 | | 3 |
| 69 | . 2006 , | | |

| | | |
|----|---|-----|
| 68 | Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. 2006 , 17, 493-9 | 8 |
| 67 | Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. 2006 , 62, 280-7 | 16 |
| 66 | Preference studies are of value to the field of sexual medicine: Con. 2006 , 3, 9-12 | |
| 65 | Sexual activity after myocardial infarction: When to resume the use of erectogenic drugs. 2006 , 3, 30-34 | 2 |
| 64 | Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference. 2006 , 7, 490-6 | 22 |
| 63 | Cardiovascular effects of phosphodiesterase 5 inhibitors. 2006 , 12, 3485-94 | 45 |
| 62 | Side effects of using nitrates to treat angina. 2006 , 5, 667-74 | 55 |
| 61 | Sex, the heart, and heart failure. 2006 , 10, 256-8 | 5 |
| 60 | Sexual dysfunction and chronic illness: the role of flexibility in coping. 2006 , 32, 235-53 | 28 |
| 59 | Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment. 2006 , 4, 173-80 | 14 |
| 58 | The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. 2007 , 19, 139-48 | 45 |
| 57 | Erectile dysfunction and hypertension. 2007 , 19, 296-302 | 67 |
| 56 | Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. 2007 , 334, 466-80 | 14 |
| 55 | Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. 2007 , 15, 76-86 | 52 |
| 54 | The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. 2007 , 19, 55-61 | 57 |
| 53 | Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials. 2007 , 153, 343-53 | 117 |
| 52 | Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction. 2007 , 6, 385-96 | 19 |
| 51 | Effect of tadalafil on anaerobic performance indices in healthy athletes. 2008 , 42, 130-3 | 15 |

| | | |
|----|--|-----|
| 50 | Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. 2007 , 19, 281-95 | 33 |
| 49 | Diagnosis and management of erectile dysfunction in the primary care setting. 2007 , 61, 1198-208 | 13 |
| 48 | Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. 2007 , 61, 1547-54 | 20 |
| 47 | Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. 2007 , 52, 990-1005 | 45 |
| 46 | [Novel indications for phosphodiesterase type 5 inhibitors]. 2007 , 102, 617-30 | 4 |
| 45 | Phosphodiesterase 5 inhibition in essential hypertension. 2008 , 10, 52-7 | 27 |
| 44 | Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins. 2008 , 5, 1066-1078 | 38 |
| 43 | Does sildenafil cause myocardial infarction or sudden cardiac death?. 2008 , 8, 1-7 | 18 |
| 42 | The cardiovascular safety of tadalafil. 2008 , 7, 43-52 | 8 |
| 41 | Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. 2008 , 32, 198-209 | 101 |
| 40 | Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. 2008 , 29, 3002-10 | 194 |
| 39 | Response to treatment with tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. 2008 , 20, 554-60 | 3 |
| 38 | Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease. 2008 , 20, 168-72 | 1 |
| 37 | Sexual dysfunction: the prima ballerina of hypertension-related quality-of-life complications. 2008 , 26, 2074-84 | 91 |
| 36 | Tadalafil in the treatment of erectile dysfunction. 2008 , 4, 1315-30 | 57 |
| 35 | Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. 2009 , 30, 1-24 | 45 |
| 34 | Factors influencing the benefit of adjunctive devices during percutaneous coronary intervention in ST-segment elevation myocardial infarction: meta-analysis and meta-regression. 2009 , 22, 49-60 | 5 |
| 33 | Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. 2009 , 3, 201-211 | 1 |

| | | |
|----|--|----|
| 32 | Phosphodiesterase 5 inhibitors: are they cardioprotective?. 2009 , 83, 204-12 | 29 |
| 31 | Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. 2010 , 122, 88-95 | 78 |
| 30 | The phosphodiesterases type 5 inhibitor tadalafil reduces the activation of the hypothalamus-pituitary-adrenal axis in men during cycle ergometric exercise. 2012 , 302, E972-8 | 14 |
| 29 | Cardiac uses of phosphodiesterase-5 inhibitors. 2012 , 59, 9-15 | 65 |
| 28 | Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. 2012 , 9, 2122-9 | 55 |
| 27 | Assessment of the effect of mirodenafil on the hemodynamics of healthy male Korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study. 2012 , 34, 1929-39 | 7 |
| 26 | Andrological aspects of physical exercise and sport medicine. 2012 , 42, 278-84 | 47 |
| 25 | Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. 2012 , 29, 771-81 | 8 |
| 24 | Antihypertensive treatment and sexual dysfunction. 2012 , 14, 285-92 | 65 |
| 23 | 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. 2012 , 9, 265-70 | 31 |
| 22 | Sexual activity and ischemic heart disease. 2014 , 16, 445 | 15 |
| 21 | Cardioprotective role of tadalafil against cisplatin-induced cardiovascular damage in rats. 2015 , 765, 574-81 | 10 |
| 20 | Preparation. 2015 , 62-112 | |
| 19 | Effects of mirodenafil on the hemodynamics in hypertensive patients taking amlodipine. 2016 , 24, 90 | |
| 18 | Technological Device for Manufacturing Transdermal Films: Possible Applications to the Individualized Treatment for Erectile Dysfunction. 2017 , 18, 2824-2831 | |
| 17 | Exercise, training, and the hypothalamic-pituitary-gonadal axis in men. 2019 , 9, 86-89 | |
| 16 | Targeting Nitric Oxide for Bone Disease. 2020 , 666-696 | 1 |
| 15 | Ruthenium Catalyzed Tandem Pictet-Spengler Reaction. 2020 , 22, 4979-4984 | 11 |

- 14 Emergency Drugs for the Oral and Maxillofacial Surgeon Office. **2022**, 34, 1-7
- 13 Sex and Chronic Physical Illness. **2017**, 479-506 2
- 12 RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity. **2019**, 129, 2318-2332 20
- 11 Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. **2006**, 1, 439-49 12
- 10 Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. **2004**, 159-181
- 9 Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. **2004**, 129-142
- 8 Drug Interaction Study of Vardenafil 20mg and Doxazosin 4mg or Tamsulosin 0.2mg in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction to Evaluate Changes in Blood Pressure. **2006**, 47, 1001
- 7 Erectile Dysfunction and Cardiovascular Disease. **2007**, 2791-2801
- 6 Advances in the Treatment of Peyronie's Disease. **2007**, 449-458
- 5 Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. **2011**, 1477-1485
- 4 Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. **2004**, 1, 185-196
- 3 Pharmacotherapy of sexual dysfunctions : current status. *Indian Journal of Psychiatry*, **2004**, 46, 213-20 2.2 5
- 2 Application of Modern Analytical Techniques for quantification of Tadalafil in Pharmaceutical and Biological Matrices: Future Prospectus.. **2022**, 19, 0
- 1 Recent Progress for the Synthesis of β -Carboline Derivatives An Update. 1-26 0